Make lower-priced versions of Humalog Mix75/25 KwikPen and Humalog Junior KwikPen available
No public evidence found either way
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 30 Jan 2020
- Due
- 15 Apr 2020
- Last checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Both insulins will have 50 percent lower list prices compared to the branded versions and will be available by mid-April.”
What we found
After 4 checks we found no clear public record either way, so this commitment is not counted as met or not met.
If you have a public source showing the outcome, please send it to us.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Make
- Deliverable
- Lower-priced Humalog Mix75/25 KwikPen and Humalog Junior KwikPen
- Target
- 50 percent
- Where
- U.S.
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-LLY-001757 · Corrections policy